January 10, 2022
CAMBRIDGE, MA — H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the addition of Richard Woodman, M.D. to its Board of Directors (“Board”).
“With over 18 years of oncology-focused pharmaceutical experience at both large and small biotechnology organizations and his years in academia, Dr. Woodman brings extensive industry and clinical knowledge to H3. His insights and guidance will be invaluable to the future growth of the company as we continue the research and development of our potential precision medicine treatments for patients with cancer,” said Dr. Takashi Owa, Ph.D., Chairman and Chief Executive Officer of H3. “Dr. Woodman has already made significant contributions since joining Eisai almost one year ago and we are delighted to welcome him to our Board.”
Dr. Woodman currently serves as Chief Clinical Officer (CCLO) of Eisai’s Oncology Business Group where he is responsible for overseeing the development of the company’s next generation oncology products, including management of design protocols, implementation of clinical trials and interpretation of trial results in preparation for applications to global regulatory authorities. Before Eisai, he served as Chief Medical Officer and Head of Research and Development at Onconova Therapeutics. Prior to that, Dr. Woodman spent 12 years at Novartis, where he served as Head of U.S. Oncology Clinical Development and Medical Affairs after his initial position of Franchise Head for Hematology in Global Medical Affairs. Previously, Dr. Woodman served as Senior Medical Director at Johnson & Johnson, where he led the oncology/hematology franchise at Ortho Biotech Products, LP.
In addition to his extensive industry expertise, Dr. Woodman spent 12 years in the Faculty of Medicine at the University of Calgary, holding several appointments including Professor in the Departments of Medicine and Oncology and Acting Head, Division of Hematology & Hematological Malignancies. He completed his hematology/oncology clinical fellowship and postdoctoral research fellowship at Scripps Clinic and Research Institute in the Department of Experimental Medicine. Dr. Woodman earned his M.D. from the University of Calgary.
“H3’s innovative and data-driven approach to precision oncology research has the potential to bring much needed therapies to patients with cancer,” said Dr. Woodman. “I am excited to join H3’s Board and help contribute to the company’s mission of advancing personalized medicines to better treat breast cancer, hepatocellular carcinoma and other advanced solid tumors.”
About H3 Biomedicine Inc.
H3 Biomedicine Inc., the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is solely focused on advancing drugs from bench to bedside. Uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics, H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. Learn more at h3biomedicine.com.